Browsing Tag
cancer screening
5 posts
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.
Exact Sciences stockholders approve Abbott acquisition, clearing final hurdle in $21bn cancer diagnostics deal
Exact Sciences stockholders approve Abbott’s $21 billion acquisition. Find out how the deal could reshape cancer diagnostics and investor strategy.
Can Freenome’s $1.1bn SPAC deal unlock a new chapter for blood-based multi-cancer detection?
Freenome merges with PCSC in $1.1B deal to go public as FRNM. Find out how its AI-powered blood tests could change early cancer detection.
GRAIL stock surges 14% after $110m Samsung deal to expand Galleri test in Asia
GRAIL stock jumps 14% after Samsung's $110M investment and Asia commercialization deal for its Galleri cancer test. Learn how investors are reacting.